IONS

Ionis Pharmaceuticals, Inc. NASDAQ

Healthcare ·Biotechnology ·US · ionispharma.com

$75.28

Mkt Cap $12.0B

52w Low $30.01 79.8% of range 52w High $86.74

50d MA $75.61 200d MA $69.37

P/E (TTM) -31.6x

EV/EBITDA -52.0x

P/B 24.6x

Debt/Equity 5.3x

ROE -35.6%

P/FCF -39.6x

RSI (14) —

ATR (14) —

Beta 0.40

50d MA $75.61

200d MA $69.37

Avg Volume 2.1M

About

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lip…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 29, 2026	BMO	-0.85	-0.56	+34.1%	71.78	+0.4%	+4.2%	+4.2%	+4.9%	—	—	—	—
Feb 25, 2026	BMO	-1.24	-1.41	-14.0%	85.45	-4.3%	-5.3%	-5.7%	-5.0%	-4.1%	-7.9%	-15.6%	—
Oct 29, 2025	BMO	-1.15	-0.61	+47.0%	73.57	-1.6%	-2.3%	+0.8%	+1.0%	+0.1%	-0.9%	+12.5%	—
Jul 30, 2025	BMO	0.27	0.86	+218.5%	41.48	+8.4%	+4.6%	+3.6%	+3.7%	+4.7%	+3.8%	+2.8%	—
Apr 30, 2025	BMO	-1.11	-0.75	+32.4%	29.81	+6.6%	+3.0%	+6.4%	+10.0%	+12.9%	+6.9%	+12.4%	—
Feb 19, 2025	BMO	-1.09	-0.66	+39.4%	31.95	+8.0%	-0.4%	+2.3%	+1.2%	-0.2%	-0.3%	+3.0%	—
Nov 6, 2024	BMO	-1.16	-0.95	+18.1%	38.80	+3.0%	+0.6%	-0.9%	+1.0%	+0.2%	-2.7%	-1.8%	—
Aug 1, 2024	BMO	-0.92	-0.45	+51.1%	49.46	+0.8%	+3.8%	-0.7%	-5.0%	-4.9%	-5.4%	-4.3%	—
May 7, 2024	BMO	-1.05	-0.98	+6.4%	42.28	-3.1%	-3.2%	-5.0%	-6.6%	-7.6%	-8.2%	-5.7%	—
Feb 21, 2024	BMO	-0.83	-0.06	+92.8%	44.35	+3.5%	-1.8%	-0.8%	+2.3%	+3.9%	+6.9%	-3.7%	—
Nov 2, 2023	BMO	-1.04	-1.03	+1.0%	45.26	+1.7%	-3.4%	+4.3%	+2.3%	+5.4%	+4.0%	+13.7%	—
Aug 9, 2023	BMO	-0.90	-0.60	+33.3%	39.55	+4.0%	+1.1%	+0.7%	+1.7%	+0.8%	+1.1%	+4.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 30	RBC Capital	Maintains	Outperform → Outperform	—	$74.83	$74.91	+0.1%	-0.1%	+0.6%	—	—	—
Apr 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$74.83	$74.91	+0.1%	-0.1%	+0.6%	—	—	—
Apr 30	Barclays	Maintains	Overweight → Overweight	—	$74.83	$74.91	+0.1%	-0.1%	+0.6%	—	—	—
Apr 23	TD Cowen	Maintains	Buy → Buy	—	$74.83	$74.96	+0.2%	-1.0%	-2.1%	-3.5%	-4.1%	+0.0%
Apr 21	Canaccord Genuity	Initiates	Buy	$110	$74.87	$75.87	+1.3%	-0.1%	-0.1%	-1.0%	-2.1%	-3.5%
Apr 21	Morgan Stanley	Maintains	Overweight → Overweight	—	$74.87	$75.87	+1.3%	-0.1%	-0.1%	-1.0%	-2.1%	-3.5%
Apr 9	BofA Securities	Maintains	Buy → Buy	—	$74.98	$74.98	+0.0%	+1.9%	+0.3%	-0.0%	+2.4%	+2.5%
Mar 26	Barclays	Maintains	Overweight → Overweight	—	$72.70	$72.25	-0.6%	+2.1%	-0.8%	-0.2%	+3.3%	+3.3%
Mar 25	Needham	Maintains	Buy → Buy	—	$69.68	$70.68	+1.4%	+4.3%	+6.5%	+3.5%	+4.1%	+7.8%
Mar 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$69.68	$70.68	+1.4%	+4.3%	+6.5%	+3.5%	+4.1%	+7.8%
Mar 3	Leerink Partners	Maintains	Outperform → Outperform	—	$81.96	$80.42	-1.9%	-4.0%	-3.1%	-8.3%	-9.7%	-8.1%
Feb 27	Piper Sandler	Maintains	Overweight → Overweight	—	$80.60	$80.59	-0.0%	+0.7%	+1.7%	-2.4%	-1.4%	-6.7%
Feb 26	Stifel	Maintains	Hold → Hold	—	$80.93	$80.32	-0.8%	-0.4%	+0.3%	+1.3%	-2.8%	-1.8%
Feb 26	Needham	Maintains	Buy → Buy	—	$80.93	$80.32	-0.8%	-0.4%	+0.3%	+1.3%	-2.8%	-1.8%
Feb 6	Piper Sandler	Maintains	Overweight → Overweight	—	$83.48	$84.85	+1.6%	+3.6%	+1.6%	+1.0%	+1.0%	-2.0%
Jan 5	Wells Fargo	Maintains	Overweight → Overweight	—	$79.67	$79.18	-0.6%	-1.4%	+2.3%	+4.4%	+2.3%	+0.8%
Dec 17	RBC Capital	Maintains	Outperform → Outperform	—	$78.37	$78.77	+0.5%	-1.6%	-0.9%	+1.5%	+3.8%	+2.5%
Dec 15	Leerink Partners	Maintains	Outperform → Outperform	—	$80.82	$80.35	-0.6%	-1.3%	-3.0%	-4.6%	-3.9%	-1.5%
Dec 9	BofA Securities	Maintains	Buy → Buy	—	$81.51	$80.55	-1.2%	-3.3%	-3.5%	-2.9%	-0.8%	-2.1%
Nov 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$73.55	$70.05	-4.8%	-5.5%	-1.5%	-1.2%	-5.0%	-2.7%
Nov 4	Piper Sandler	Maintains	Overweight → Overweight	—	$73.65	$72.40	-1.7%	-1.0%	+1.4%	+0.6%	-0.1%	-5.6%
Oct 30	Raymond James	Maintains	Strong Buy → Strong Buy	—	$71.88	$71.91	+0.0%	+3.2%	+3.4%	+2.5%	+1.4%	+3.9%
Oct 30	TD Cowen	Maintains	Buy → Buy	—	$71.88	$71.91	+0.0%	+3.2%	+3.4%	+2.5%	+1.4%	+3.9%
Oct 30	Barclays	Maintains	Overweight → Overweight	—	$71.88	$71.91	+0.0%	+3.2%	+3.4%	+2.5%	+1.4%	+3.9%
Oct 30	RBC Capital	Maintains	Outperform → Outperform	—	$71.88	$71.91	+0.0%	+3.2%	+3.4%	+2.5%	+1.4%	+3.9%
Oct 30	Needham	Maintains	Buy → Buy	—	$71.88	$71.91	+0.0%	+3.2%	+3.4%	+2.5%	+1.4%	+3.9%
Oct 30	Morgan Stanley	Maintains	Overweight → Overweight	—	$71.88	$71.91	+0.0%	+3.2%	+3.4%	+2.5%	+1.4%	+3.9%
Oct 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$71.88	$71.91	+0.0%	+3.2%	+3.4%	+2.5%	+1.4%	+3.9%
Oct 16	Morgan Stanley	Maintains	Overweight → Overweight	—	$72.39	$73.12	+1.0%	+0.9%	+1.0%	+1.6%	-1.0%	-1.2%
Oct 8	Oppenheimer	Maintains	Outperform → Outperform	—	$68.94	$70.49	+2.2%	+1.5%	+1.9%	+1.5%	+2.4%	+3.5%
Oct 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$68.94	$70.49	+2.2%	+1.5%	+1.9%	+1.5%	+2.4%	+3.5%
Oct 8	Needham	Maintains	Buy → Buy	—	$68.94	$70.49	+2.2%	+1.5%	+1.9%	+1.5%	+2.4%	+3.5%
Oct 8	JP Morgan	Upgrade	Neutral → Overweight	—	$68.94	$70.49	+2.2%	+1.5%	+1.9%	+1.5%	+2.4%	+3.5%
Oct 6	Stifel	Maintains	Hold → Hold	—	$69.15	$69.15	+0.0%	-0.2%	-0.3%	+1.2%	+1.6%	+1.2%
Sep 26	Goldman Sachs	Upgrade	Sell → Neutral	—	$62.97	$64.03	+1.7%	+1.8%	+1.9%	+3.9%	+4.5%	+8.6%
Sep 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$61.36	$61.51	+0.2%	+2.0%	+4.2%	+2.6%	+4.4%	+4.5%
Sep 23	Barclays	Maintains	Overweight → Overweight	—	$61.36	$61.51	+0.2%	+2.0%	+4.2%	+2.6%	+4.4%	+4.5%
Sep 23	Guggenheim	Maintains	Buy → Buy	—	$61.36	$61.51	+0.2%	+2.0%	+4.2%	+2.6%	+4.4%	+4.5%
Sep 23	Morgan Stanley	Maintains	Overweight → Overweight	—	$61.36	$61.51	+0.2%	+2.0%	+4.2%	+2.6%	+4.4%	+4.5%
Sep 23	BofA Securities	Maintains	Buy → Buy	—	$61.36	$61.51	+0.2%	+2.0%	+4.2%	+2.6%	+4.4%	+4.5%
Sep 4	RBC Capital	Maintains	Outperform → Outperform	—	$60.49	$59.34	-1.9%	-1.9%	+1.2%	+0.8%	+6.5%	+5.8%
Sep 3	Citigroup	Maintains	Buy → Buy	—	$57.49	$58.98	+2.6%	+5.2%	+3.2%	+6.5%	+6.1%	+12.0%
Sep 3	Barclays	Maintains	Overweight → Overweight	—	$57.49	$58.98	+2.6%	+5.2%	+3.2%	+6.5%	+6.1%	+12.0%
Sep 3	Goldman Sachs	Maintains	Sell → Sell	—	$57.49	$58.98	+2.6%	+5.2%	+3.2%	+6.5%	+6.1%	+12.0%
Sep 3	BMO Capital	Upgrade	Market Perform → Outperform	—	$57.49	$58.98	+2.6%	+5.2%	+3.2%	+6.5%	+6.1%	+12.0%
Sep 2	Needham	Maintains	Buy → Buy	—	$42.64	$49.14	+15.2%	+34.8%	+41.9%	+39.2%	+43.6%	+43.1%
Sep 2	Jefferies	Maintains	Buy → Buy	—	$42.64	$49.14	+15.2%	+34.8%	+41.9%	+39.2%	+43.6%	+43.1%
Sep 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$42.64	$49.14	+15.2%	+34.8%	+41.9%	+39.2%	+43.6%	+43.1%
Aug 25	Needham	Maintains	Buy → Buy	—	$42.69	$42.82	+0.3%	-2.0%	-1.2%	+0.1%	-0.2%	-0.1%
Aug 25	JP Morgan	Maintains	Neutral → Neutral	—	$42.69	$42.82	+0.3%	-2.0%	-1.2%	+0.1%	-0.2%	-0.1%

Recent Filings

8-K

Ionis Pharmaceuticals, Inc. -- 8-K Filing

Ionis Pharmaceuticals issued a press release on April 29, 2026, but the specific business development or financial impact cannot be determined from this limited filing summary.

Apr 29

8-K · 8.01 !! High

Ionis Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement

Ionis Pharmaceuticals reported positive pivotal study results for zilganersen treating AxD, a rare neurological disease, strengthening prospects for regulatory approval and potential market entry in an underserved patient population.

Apr 21

8-K · 5.02 !!! Very High

Ionis Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change

B. Lynne Parshall departed Ionis Pharmaceuticals' board on March 3, 2026, reducing board oversight capacity and potentially signaling internal governance shifts that investors should monitor.

Mar 9

8-K

Ionis Pharmaceuticals, Inc. -- 8-K Filing

I cannot provide a meaningful analysis based on this summary, as it lacks substantive deal or business information—it only references a press release date without disclosing actual news content or financial terms.

Feb 25

Data updated apr 25, 2026 3:58pm · Source: massive.com